Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6990929 | 1.00 | MDM2 (0.81) | MDM2CYP1A2CTNNB1ALPIPKM | |
| SCHEMBL7164412 | 1.00 | MDM2 (0.81) | MDM2CYP1A2CTNNB1ALPIPKM | |
| SCHEMBL11713368 | 0.90 | MDM2 (1.00) | MDM2CYP1A2CTNNB1ALPIPKM | |
| SCHEMBL7037701 | 0.88 | MDM2 (0.88) | MDM2CYP1A2CTNNB1ALPIPKM | |
| SCHEMBL3355858 | 0.88 | MDM2 (0.88) | MDM2CYP1A2CTNNB1ALPIPKM | |
| SCHEMBL7349956 | 0.86 | CYP1A2 (0.59) | MDM2CYP1A2ALPIPKMPTGS1 | |
| SCHEMBL9242408 | 0.83 | MDM2 (0.79) | MDM2CYP1A2CTNNB1ALPIPKM | |
| SCHEMBL6990924 | 0.83 | MDM2 (0.79) | MDM2CYP1A2CTNNB1ALPIPKM | |
| SCHEMBL2138695 | 0.83 | MDM2 (0.79) | MDM2CYP1A2CTNNB1ALPIPKM | |
| SCHEMBL7164409 | 0.83 | MDM2 (0.79) | MDM2CYP1A2CTNNB1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0641343-B1 | 4-MERCAPTOACETYLAMINO-[2] BENZAZEPINONE(3) DERIVATIVES, AND USE AS ENKEPHALINASE INHIBITORS | MERRELL PHARMA INC (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6544980-B2 | For treating neoplasms, atherosclerosis, and chronic inflammatory diseases | AVENTIS PHARMACEUTICALS INC. | 2003-04-08 | — | — | US | disclosed |
| CN-1100785-C | 1,3,4, 5-tetrahydrobenzo [ C ] azepine * -3-one disulfide derivatives and methods | MERVELL DOW PHARMACEUTICALS IN (US) | 2003-02-05 | — | — | CN | disclosed |
| US-20020095035-A1 | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase | WARSHAWSKY ALAN M (US) | 2002-07-18 | — | — | US | disclosed |
| EP-1150957-A1 | N-CARBOXYMETHYL SUBSTITUTED BENZOLACTAMS AS INHIBITORS OF MATRIX METALLOPROTEINASE | Aventis Pharmaceuticals Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000040564-A1 | N-CARBOXYMETHYL SUBSTITUTED BENZOLACTAMS AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| EP-0750631-B1 | NOVEL MERCAPTOACETYLAMIDO 1,3,4,5-TETRAHYDRO-BENZO(C)AZEPIN-3-ONE DISULFIDE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | MERRELL PHARMA INC (US) | 2000-04-05 | — | — | EP | disclosed |
| US-5880119-A | Mercaptoacetylamino 1,3,4,5-tetrahydro-benzo(C)azepin-2-one disulfide derivatives useful as inhibitors of enkephalinase and ACE | MERRELL PHARMACEUTICALS INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5731306-A | Mercaptoacetylamido 1,3,4,5-tetrahydro-benzo c!azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace | AVENTISUB II INC. | 1998-03-24 | — | — | US | disclosed |
| EP-0481522-B1 | Novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace | MERRELL PHARMA INC (US) | 1997-12-29 | — | — | EP | disclosed |
| CN-1140454-A | Novel mercaptoacetylamido-1,3,4,5-tetrahydro-benzo[c] azepin-3-one disulfide derivs. useful as inhibitors of enkephalinase and ACE | MERRELL DOW PHARMA (US) | 1997-01-15 | — | — | CN | disclosed |
| EP-0750631-A1 | NOVEL MERCAPTOACETYLAMIDO 1,3,4,5-TETRAHYDRO-BENZO(C)AZEPIN-3-ONE DISULFIDE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | MERRELL PHARMACEUTICALS INC. (US) | 1997-01-02 | — | — | EP | disclosed |
| US-5527795-A | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace | MERRELL PHARMACEUTICALS INC. (US) | 1996-06-18 | — | — | US | disclosed |
| US-5491143-A | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1996-02-13 | — | — | US | disclosed |
| WO-1995021854-A1 | NOVEL MERCAPTOACETYLAMIDO 1,3,4,5-TETRAHYDRO-BENZO[C]AZEPIN-3-ONE DISULFIDE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE | MERRELL PHARMACEUTICALS INC. (US) | 1995-08-17 | — | — | WO | disclosed |
| US-5430145-A | Analgesics, reduction of drug withdrawal symptoms, hypotensive agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0641343-A1 | 4-MERCAPTOACETYLAMINO- 2] BENZAZEPINONE(3) DERIVATIVES, AND USE AS ENKEPHALINASE INHIBITORS | MERRELL PHARMACEUTICALS INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023397-A1 | 4-MERCAPTOACETYLAMINO-[2] BENZAZEPINONE(3) DERIVATIVES, AND USE AS ENKEPHALINASE INHIBITORS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5238932-A | Mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0481522-A1 | Novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace | MERRELL PHARMACEUTICALS INC. (US) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095035-A1 | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase | MMP17, MMP26, MMP16 | MDM2 2532/4885CYP1A2 648/4885CTNNB1 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.